Opioid extended-release tablets with improved tamper-resistant properties

Objective: To prepare a polyethylene oxide-based tablet with high mechanical strength that would release an opioid for once- or twice-daily administration. This tablet would also create barriers against crushing and subsequent preparation steps for abuse and misuse that are not present in conventional opioid formulations. Research design & methods: Innovative manufacturing processes were created by applying heat and force simultaneously, using tramadol HCl as model compound; production scale testing used oxymorphone HCl. Standardized in vitro crush force and extraction tests were performed. Results & discussion: A production scale manufacturing process using hot melt extrusion of a strand, cooling, slicing and shaping the slices into tablet form produced stable oxymorphone extended-release (ER) tablets with in vitro dissolution characteristics similar to commercial oxymorphone ER. The tablets resisted crushing by spoons, pill crushers and a hammer and resisted extraction in a test battery of solvents. The standardized tampering methods used here do not include all methods an abuser might employ. Postmarketing data will be needed to determine the actual impact of tamper resistance mechanisms on opioid abuse rates. Conclusions: This purely mechanical approach to tamper resistance may make a tablet less attractive for abuse without exposing compliant patients to new risks associated with opioid antagonists or aversive compounds. A compliant patient's risk of adverse events may be reduced by the tablet's resistance to accidental crushing.

[1]  H. Omidian,et al.  Current approaches in tamper-resistant and abuse-deterrent formulations , 2013, Drug development and industrial pharmacy.

[2]  S. Vosburg,et al.  Assessment of a formulation designed to be crush-resistant in prescription opioid abusers. , 2012, Drug and alcohol dependence.

[3]  S. Butler,et al.  Effects of reformulated OxyContin® among patients assessed for substance abuse treatment in the NAVIPPRO sentinel surveillance network , 2012 .

[4]  Nathaniel Katz,et al.  A Brief Survey to Characterize Oxycodone Abuse Patterns in Adolescents Enrolled in Two Substance Abuse Recovery High Schools , 2012, The American journal of drug and alcohol abuse.

[5]  W. Fiske,et al.  Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release , 2011, Drug design, development and therapy.

[6]  S. Butler,et al.  Abuse risks and routes of administration of different prescription opioid compounds and formulations , 2011, Harm reduction journal.

[7]  안야 가이쓸러,et al.  Tamper-resistant dosage form for oxidation-sensitive opioids , 2010 .

[8]  S. Butler,et al.  Estimating attractiveness for abuse of a not-yet-marketed "abuse-deterrent" prescription opioid formulation. , 2010, Pain medicine.

[9]  D. Juurlink,et al.  Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone , 2009, Canadian Medical Association Journal.

[10]  Nathaniel Katz Abuse-deterrent opioid formulations: Are they a pipe dream? , 2008, Current rheumatology reports.

[11]  볼프강 플라이셔,et al.  Tamper resistant dosage forms , 2007 .

[12]  요하네스 바르톨로모이스,et al.  Dosage form that is safeguarded from abuse , 2004 .

[13]  John Mitchell Oral Dosage Forms that should not be Crushed or Chewed , 2002 .